Select Language
SOD1
SOD1 Overview
| English Name | Superoxide dismutase | Approved Drugs | 3 |
| Drugs in Clinical Trials | 13 | Target Synonym | SOD1，Superoxide Dismutase 1，HSod1，Amyotrophic Lateral Sclerosis 1 (Adult)，Epididymis Secretory Protein Li 44，Superoxide Dismutase [Cu-Zn]，Cu/Zn Superoxide Dismutase，Indophenoloxidase A，SOD， Soluble，EC 1.15.1.1，HEL-S-44，IPOA，ALS1，SOD，ALS，Superoxide Dismutase，STAHP，EC:1.15.1.1，Superoxide Dismutase 1， Soluble，Superoxide Dismutase， Cystolic，Homodimer |
| Highest Development Stage | Approved | ||
| English Name | Superoxide dismutase |
| Target Synonym | SOD1，Superoxide Dismutase 1，HSod1，Amyotrophic Lateral Sclerosis 1 (Adult)，Epididymis Secretory Protein Li 44，Superoxide Dismutase [Cu-Zn]，Cu/Zn Superoxide Dismutase，Indophenoloxidase A，SOD， Soluble，EC 1.15.1.1，HEL-S-44，IPOA，ALS1，SOD，ALS，Superoxide Dismutase，STAHP，EC:1.15.1.1，Superoxide Dismutase 1， Soluble，Superoxide Dismutase， Cystolic，Homodimer |
| Approved Drugs | 3 |
| Drugs in Clinical Trials | 13 |
| Highest Development Stage | Approved |
SOD1 Product List
- Product Category
Protein (1)
- Product Status
Launched (1)
- Species
Human (1)
- Tag
His Tag (1)
- Conjugate
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
SO1-H5148 |  Human | E. coli | Human SOD1 / Cu-Zn SOD Protein, His Tag, low Endotoxin (active enzyme) |  |  |
Total: 1
- 1
SOD1 Background
Superoxide dismutase [Cu-Zn] (SOD1) is also known as superoxide dismutase 1 (hSod1), an enzyme that in humans is encoded by the SOD1 gene, located on chromosome 21. SOD1 can bind copper and zinc ions and is one of three superoxide dismutases responsible for destroying free superoxide radicals in the body. The encoded isozyme (SOD1) is a soluble cytoplasmic and mitochondrial intermembrane space protein, acting as a homodimer to convert naturally occurring, but harmful, superoxide radicals to molecular oxygen and hydrogen peroxide. Furthermore, the mutations of SOD1 gene can result in a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord.
SOD1 Synonyms
SOD1,Superoxide dismutase 1,hSod1
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Otaplimastat | SP-8203 hydrochloride; SP8203 HCL; SP-8203 | Phase 3 Clinical | Shin Poong Pharmaceutical Co Ltd | Ischemic Stroke | Details |
| Bis-choline tetrathiomolybdate | ATN-224; WTX-101; ALXN-1840 | Phase 2 Clinical | Wilson Therapeutics | Hepatolenticular Degeneration; Melanoma; Multiple Myeloma; Prostatic Neoplasms | Details |
| Superoxide dismutase (Ube Industries) | r-hSOD; FKU-871 | Phase 2 Clinical | Astellas Pharma Inc, Ube Industries Ltd | Diabetic Neuropathies; Myocardial Ischemia | Details |
| BMX-010 | BMX-010; MnTE-2-PyP; MnTE-2-PyP5+ | Phase 2 Clinical | Duke University | Acne Vulgaris; Dermatitis, Atopic; Psoriasis; Rosacea | Details |
| Tempol | MBM-02; OT-674; NSC-142784; MTS-02; MTS-10; MTS-01; APC-410; APC-400; REC-994; MBM-01; REC-0000994 | Phase 2 Clinical | Mitos | Alopecia; Anus Neoplasms; Ataxia Telangiectasia; Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Glioblastoma; Hemangioma, Cavernous, Central Nervous System; Mucositis; Ototoxicity; Prostatic Neoplasms | Details |
| Superoxide dismutase analogue (LTT Bio-Pharma) | LT-1001; LT-0011; PC-SOD NE; PC-SOD; LT-1002 | Phase 2 Clinical | LTT Bio-Pharma Co Ltd | Colitis, Ulcerative; Idiopathic Pulmonary Fibrosis; Myocardial Infarction; Peripheral Nervous System Diseases; Respiratory Distress Syndrome, Adult; Stroke | Details |
| RAG-17 | RAG-17; RD-12500 | Phase 2 Clinical | Ractigen Therapeutics (Nantong) Co Ltd | Amyotrophic Lateral Sclerosis | Details |
| ALN-SOD | ALN-SOD | Phase 2 Clinical | Alnylam Pharmaceuticals Inc | Amyotrophic Lateral Sclerosis | Details |
| NI-005 | AP-101 (AL-S Pharma); NI-005 | Phase 2 Clinical | Al-S Pharma Ag | Amyotrophic Lateral Sclerosis | Details |
| APB-102 | APB-102; AMT-162 | Phase 2 Clinical | University Of Massachusetts Medical School | Amyotrophic Lateral Sclerosis | Details |
| NAS150 | AEOL-10150; NAS150; NAS-150 | Phase 1 Clinical | Aeolus Pharmaceuticals | Idiopathic Pulmonary Fibrosis; Lung Injury; Neoplasms; Supranuclear Palsy, Progressive | Details |
| INS-1202 | INS1202; INS-1202 | Phase 1 Clinical | Insmed | Amyotrophic Lateral Sclerosis | Details |
| [89Zr]Zr-DFO-AP-101 | Phase 1 Clinical | Université De Sherbrooke | Amyotrophic Lateral Sclerosis; Tooth Diseases | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Orgotein | Approved | Gt Biopharma Inc | Ontosein | Spain | Rheumatic Diseases; Cystitis; Radiation Injuries | null | 1996-01-01 | Cystitis; Radiation Injuries; Rheumatic Diseases | Details | |
| Cupric Sulfate/Manganese sulfate/Selenious acid/Zinc Sulfate | Approved | American Regent Inc | MULTRYS | United States | Dietary Supplement | American Regent Inc | 2020-07-02 | Dietary Supplement | Details | |
| Tofersen | 99mTc-MAG3-BIIB067; ISIS-333611; BIIB-067; SODr/h333611; ISIS-SOD1Rx; IONIS SOD1Rx | Approved | Ionis Pharmaceuticals Inc, Ludwig Institute For Cancer Research | QALSODY, Qalsody, 凯盛迪 | United States | Amyotrophic Lateral Sclerosis | Biogen Ma Inc, Biogen Inc | 2023-04-25 | Amyotrophic Lateral Sclerosis; Familial Amyotrophic Lateral Sclerosis | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland